Balanced news tone
News Sentiment
HAE sentiment intelligence
Haemonetics Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
68 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+1.5% over one week, -2.6% over four weeks, trend inactive, and near fair-value range.
Haemonetics Price Target Raised to $90.00/Share From $85.00 by Mizuho
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
78/100 classification
One-week reaction
1.5%
Price digesting
Trend fit
Trend inactive
-2.6% over four weeks
Fair value
2.2%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
51
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Moomoo
Direct company coverage
Haemonetics Price Target Raised to $90.00/Share From $85.00 by Mizuho
Mizuho has raised its price target for Haemonetics (NYSE: HAE) to $90.00 per share, an increase from the previous target of $85.00. This adjustment in the price target indicates an updated valuation of the company by the analyst firm.
- Tone
- Positive 73/100
- Event
- Analyst action
- Published
- 16 Jul 2026 00:12
- Source
- Moomoo
Moomoo
Direct company coverage
Haemonetics Is Maintained at Outperform by Mizuho
Mizuho has maintained its Outperform rating on Haemonetics (NYSE: HAE) with a price target of $125.00. This continued positive outlook suggests the analyst firm believes in the company's strong performance potential. Investors will likely watch Haemonetics' future financial resul
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 15 Jul 2026 19:12
- Source
- Moomoo
GuruFocus
Direct company coverage
HAE Maintained by Mizuho -- Price Target Raised to $90
Mizuho has maintained an Outperform rating for Haemonetics (HAE), raising its price target from $85.00 to $90.00. GuruFocus identifies HAE as 10.5% undervalued with a strong GF Score™ of 87/100, citing high profitability, growth potential, and attractive valuation. Insiders have
- Tone
- Positive 80/100
- Event
- Analyst action
- Published
- 15 Jul 2026 19:10
- Source
- GuruFocus
GuruFocus
Direct company coverage
Is Haemonetics Corp (HAE) a Bargain After 3.2% Drop? GF Value Sa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 00:25
- Source
- GuruFocus
Market source
Industry context
Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q1 Earnings: Integer Holdings (NYSE:ITGR)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 18:07
- Source
- Market source
TradingView
Direct company coverage
HAE5817431 Bond Profile — Key Metrics
This article provides key metrics for the Haemonetics Corporation 2.5% 01-JUN-2029 bond (HAE5817431 FINRA). It details the issuer's description, issue and maturity dates, outstanding amount, face value, and coupon rate. The bond profile also includes a company overview of Haemone
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 14:39
- Source
- TradingView
simplywall.st
Direct company coverage
Haemonetics (HAE) Joins Russell Indexes As Investors Ask If The Stock Is Still Undervalued
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 00:02
- Source
- simplywall.st
MSN
Direct company coverage
Raymond James Downgrades Haemonetics (HAE)
Raymond James has downgraded Haemonetics (HAE) stock from an "Outperform" rating to a "Market Perform" rating. This change reflects the analyst's updated view on the company's financial prospects and stock performance. Investors and market watchers often follow such downgrades as
- Tone
- Negative 15/100
- Event
- Analyst action
- Published
- 10 Jul 2026 15:10
- Source
- MSN
Moomoo
Direct company coverage
Press Release: Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Haemonetics has announced that it will release its first quarter fiscal year 2027 financial results on Thursday, August 6, 2026. The company will also host a conference call and webcast on the same day at 8:00 a.m. EDT to discuss these results. Interested parties can access the w
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 17:39
- Source
- Moomoo
Ad-hoc-news.de
Direct company coverage
HAE stock holds steady as investors track Haemonetics' product mix
Haemonetics (HAE) stock remains in focus due to its blood-management and hospital product offerings, which form the core of its business model. The company, listed on the NYSE, specializes in medical technology for blood collection, plasma processing, and hospital workflows, rely
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 15:39
- Source
- Ad-hoc-news.de
www.marketscreener.com
Direct company coverage
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Haemonetics Corporation announced it will publish its first quarter fiscal year 2027 financial results on Thursday, August 6, 2026, at 6:00 am ET. The company will also host a conference call for investors and analysts at 8:00 am ET on the same day to discuss the results and answ
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Jul 2026 20:10
- Source
- www.marketscreener.com
Stock Titan
Direct company coverage
Haemonetics sets Aug. 6 call for Q1 2027 results
Haemonetics (NYSE: HAE) has announced that it will publish its first-quarter fiscal year 2027 financial results on Thursday, August 6, 2026, at 6:00 a.m. ET. The company will also host a conference call for investors and analysts at 8:00 a.m. ET on the same day to discuss the res
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Jul 2026 20:10
- Source
- Stock Titan
AD HOC NEWS
Direct company coverage
Haemonetics Corp updates investors on blood management business. Operational focus supports long-ter HAEMONETICS CORP updates investors on blood management business. Operational focus supports long-term growth outlook
Haemonetics Corp, a medical technology company specializing in blood management systems, continues to update investors on its operational focus. The company invests in core platforms and software tools to support hospitals and blood centers globally, aiming to improve patient car
- Tone
- Positive 73/100
- Event
- Guidance
- Published
- 06 Jul 2026 12:11
- Source
- AD HOC NEWS
TradingView
Direct company coverage
Enterprise value to EBIT forward of Haemonetics Corporation – SWB:HAZ
This article provides financial information for Haemonetics Corporation (SWB:HAZ), specifically focusing on its enterprise value to EBIT forward. It indicates that the market was closed with no trades recorded and presents a navigation link to financial data on TradingView.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 00:11
- Source
- TradingView
TradingView
Direct company coverage
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Haemonetics Corporation (HAE) is poised for growth driven by its Plasma franchise and the NexSys PCS system. Despite strong performance in its Plasma business and the potential of new technology, concerns remain regarding its debt-burdened balance sheet and competitive market. Th
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 03 Jul 2026 17:10
- Source
- TradingView
AD HOC NEWS
Direct company coverage
Haemonetics Corp updates plasma strategy, shares tracked against U.S. medtech peers
Haemonetics Corp is adjusting its plasma collection strategy and focusing on growth in its key business lines, particularly automated plasmapheresis platforms and blood management systems for hospitals. The company provides equipment and software for plasma centers rather than ow
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 18:39
- Source
- AD HOC NEWS
marketscreener.com
Direct company coverage
Haemonetics Corporation(NYSE: HAE) added to Russell 2500 Value Benchmark
Haemonetics Corporation (NYSE: HAE), a medical technology company specializing in blood and plasma technologies, has been added to the Russell 2500 Value Benchmark. This inclusion is part of several recent additions to various Russell indices, reflecting increased recognition and
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 29 Jun 2026 12:40
- Source
- marketscreener.com
www.marketscreener.com
Direct company coverage
Haemonetics Corporation(NYSE: HAE) added to Russell 2000 Value Benchmark
Haemonetics Corporation (NYSE: HAE), a medical technology company, has been added to the Russell 2000 Value Benchmark. This update reflects the company's position within the small-cap value segment of the market. The article also provides recent news and financial data for Haemon
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 11:39
- Source
- www.marketscreener.com
marketscreener.com
Direct company coverage
Haemonetics Corporation(NYSE: HAE) added to Russell 2000 Value-Defensive Index
Haemonetics Corporation (NYSE: HAE) has been added to the Russell 2000 Value-Defensive Index. This medical technology company specializes in solutions for critical medical needs, including hospital technologies, plasma collection, and blood center products. The addition to the in
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Jun 2026 02:11
- Source
- marketscreener.com
Simply Wall Street
Direct company coverage
Haemonetics’ Broad Russell Value Index Inclusion Might Change The Case For Investing In Haemonetics (HAE)
Haemonetics Corporation (HAE) has been included in several Russell value and defensive indexes, which is expected to increase passive ownership and liquidity, reinforcing its position as a value-tilted medtech stock. While this inclusion will impact trading dynamics, the core inv
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 29 Jun 2026 01:11
- Source
- Simply Wall Street
TradingView
Direct company coverage
Enterprise value to revenue forward of Haemonetics Corporation – NYSE:HAE
This article provides financial information for Haemonetics Corporation (NYSE: HAE), specifically detailing its enterprise value to revenue forward metric. The content, sourced from TradingView, focuses on the company's financials within the Health Technology sector.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 15:40
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Haemonetics Corporation – NYSE:HAE
This article from TradingView displays the "Price to sales forward" financial metric for Haemonetics Corporation (NYSE:HAE). The page appears to be a financial data presentation without explanatory text, showing only the period, value, and change for this specific metric. It is p
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 12:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Haemonetics Corporation – FWB:HAZ
This page provides financial data for Haemonetics Corporation (HAZ) on the Frankfurt Stock Exchange, specifically focusing on its enterprise value to revenue forward. It is a data-centric page without a narrative article.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 12:40
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Haemonetics Corporation – FWB:HAZ
This page from TradingView provides financial data for Haemonetics Corporation (FWB:HAZ), specifically its price to sales forward. It shows that the market is currently closed with no trades recorded for the stock. The content focuses purely on this financial metric without furth
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 01:09
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Haemonetics Corporation – NYSE:HAE
This page provides financial information for Haemonetics Corporation (NYSE: HAE), specifically detailing its forward Price to Earnings (P/E) ratio. The content is primarily a financial data point from TradingView, indicating no current trades for the company and listing various f
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 22:09
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Haemonetics Corporation – FWB:HAZ
This page from TradingView provides financial information for Haemonetics Corporation (FWB:HAZ), specifically focusing on its Price to Earnings (forward) metric. It lists the company on the Frankfurt Stock Exchange within the Health Technology and Medical Specialties sectors. The
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 18:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Haemonetics Corporation – NYSE:HAE
This article presents financial information for Haemonetics Corporation (NYSE: HAE), specifically focusing on its Enterprise Value to EBITDA (EV/EBITDA) forward metric. It highlights that this data point is accessible through the TradingView platform, which provides various finan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 10:40
- Source
- TradingView
TradingView
Direct company coverage
Haemonetics Corporation Actuals & Estimates (NYSE:HAE)
This article provides financial actuals and estimates for Haemonetics Corporation (NYSE: HAE), including details on its stock performance, analyst forecasts, earnings, revenue, and market capitalization. It highlights the company's recent stock price movements, upcoming earnings
- Tone
- Positive 67/100
- Event
- Earnings
- Published
- 26 Jun 2026 03:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Haemonetics Corporation – SWB:HAZ
This article provides financial data for Haemonetics Corporation (SWB:HAZ) on the Stuttgart Stock Exchange, specifically focusing on its Enterprise Value to EBITDA forward. The content appears to be a stub or a section within a larger financial platform, offering no specific valu
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 02:40
- Source
- TradingView
GuruFocus
Direct company coverage
Haemonetics Corp (HAE) Stock Up 6.5% and Still Undervalued -- GF Score: 84/100
Haemonetics Corp (HAE) saw its stock rise by 6.5% to $77.62 on June 25, 2026, and is considered 8.5% undervalued compared to its GF Value™ of $84.82. The company holds a strong GF Score™ of 84/100, driven by high profitability and growth ranks, despite a neutral stance from insid
- Tone
- Positive 81/100
- Event
- Market update
- Published
- 26 Jun 2026 00:40
- Source
- GuruFocus